Artiva Biotherapeutics, Inc. Common Stock (ARTV)vsModerna Inc (MRNA)
ARTV
Artiva Biotherapeutics, Inc. Common Stock
$7.72
-4.57%
HEALTHCARE · Cap: $499.66M
MRNA
Moderna Inc
$182.11
-0.25%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
ARTV leads profitability with a 0.0% profit margin vs -141.4%. ARTV earns a higher WallStSmart Score of 29/100 (F).
ARTV
Avoid29
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARTV.
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$182.11
$47.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Trading at 10.7x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARTV
The strongest argument for ARTV centers on Price/Book, Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ARTV
The primary concerns for ARTV are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ARTV profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
ARTV carries more volatility with a beta of 2.20 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
ARTV generates stronger free cash flow (-42M), providing more financial flexibility.
Bottom Line
ARTV scores higher overall (29/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artiva Biotherapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Artiva Biotherapeutics, Inc. is a cutting-edge biotechnology firm dedicated to revolutionizing cancer therapy through its proprietary natural killer (NK) cell platform. With a promising pipeline targeting both hematologic and solid tumors, the company is at the forefront of innovation in the dynamic field of immuno-oncology. Leveraging its commitment to scientific excellence and strategic collaborations, Artiva is strategically positioned to advance its clinical candidates, thereby significantly improving patient outcomes in the fight against cancer. As it progresses through crucial clinical trials, the company's innovative approach holds the potential to reshape cancer treatment paradigms.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?